FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223493340> ?p ?o ?g. }

• W4223493340 endingPage "2169" @default.
• W4223493340 startingPage "2159" @default.
• W4223493340 abstract "Maintenance of functioning and well-being during the progression-free survival (PFS) period is important for glioma patients. This study aimed to determine whether health-related quality of life (HRQoL) can be maintained during progression-free time, and factors associated with HRQoL deterioration in this period.We included longitudinal HRQoL data from previously published clinical trials in glioma. The percentage of patients with stable HRQoL until progression was determined per scale and at the individual patient level (i.e. considering all scales simultaneously). We assessed time to a clinically relevant deterioration in HRQoL, expressed in deterioration-free survival and time-to-deterioration (the first including progression as an event). We also determined the association between sociodemographic and clinical factors and HRQoL deterioration in the progression-free period.Five thousand five hundred and thirty-nine patients with at least baseline HRQoL scores had a median time from randomization to progression of 7.6 months. Between 9-29% of the patients deteriorated before disease progression on the evaluated HRQoL scales. When considering all scales simultaneously, 47% of patients deteriorated on ≥1 scale. Median deterioration-free survival period ranged between 3.8-5.4 months, and median time-to-deterioration between 8.2-11.9 months. For most scales, only poor performance status was independently associated with clinically relevant HRQoL deterioration in the progression-free period.HRQoL was maintained in only 53% of patients in their progression-free period, and treatment was not independently associated with this deterioration in HRQoL. Routine monitoring of the patients' functioning and well-being during the entire disease course is therefore important, so that interventions can be initiated when problems are signaled." @default.
• W4223493340 created "2022-04-15" @default.
• W4223493340 creator A5010791019 @default.
• W4223493340 creator A5010891460 @default.
• W4223493340 creator A5015612720 @default.
• W4223493340 creator A5017177249 @default.
• W4223493340 creator A5027431274 @default.
• W4223493340 creator A5031777632 @default.
• W4223493340 creator A5034105859 @default.
• W4223493340 creator A5036818390 @default.
• W4223493340 creator A5038129366 @default.
• W4223493340 creator A5053052330 @default.
• W4223493340 creator A5053255415 @default.
• W4223493340 creator A5056837393 @default.
• W4223493340 creator A5066122910 @default.
• W4223493340 creator A5066290988 @default.
• W4223493340 creator A5079004439 @default.
• W4223493340 creator A5080482957 @default.
• W4223493340 creator A5085405152 @default.
• W4223493340 creator A5087336206 @default.
• W4223493340 creator A5087782965 @default.
• W4223493340 creator A5088995687 @default.
• W4223493340 date "2022-04-11" @default.
• W4223493340 modified "2023-10-04" @default.
• W4223493340 title "Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period" @default.
• W4223493340 cites W1959628099 @default.
• W4223493340 cites W1965397926 @default.
• W4223493340 cites W1977392502 @default.
• W4223493340 cites W2014671160 @default.
• W4223493340 cites W2015737413 @default.
• W4223493340 cites W2018304470 @default.
• W4223493340 cites W2021199808 @default.
• W4223493340 cites W2025587609 @default.
• W4223493340 cites W2039600670 @default.
• W4223493340 cites W2041214079 @default.
• W4223493340 cites W2072044537 @default.
• W4223493340 cites W2099975398 @default.
• W4223493340 cites W2118311655 @default.
• W4223493340 cites W2129769436 @default.
• W4223493340 cites W2133865472 @default.
• W4223493340 cites W2141595244 @default.
• W4223493340 cites W2146039571 @default.
• W4223493340 cites W2156463516 @default.
• W4223493340 cites W2162193371 @default.
• W4223493340 cites W2162643152 @default.
• W4223493340 cites W2165772224 @default.
• W4223493340 cites W2167571044 @default.
• W4223493340 cites W2195040438 @default.
• W4223493340 cites W2526176932 @default.
• W4223493340 cites W2577801124 @default.
• W4223493340 cites W2768388636 @default.
• W4223493340 cites W2784162614 @default.
• W4223493340 cites W2793795701 @default.
• W4223493340 cites W2808884557 @default.
• W4223493340 cites W2808979164 @default.
• W4223493340 cites W2914215391 @default.
• W4223493340 cites W2955554324 @default.
• W4223493340 cites W3005722021 @default.
• W4223493340 cites W3131616524 @default.
• W4223493340 doi "https://doi.org/10.1093/neuonc/noac097" @default.
• W4223493340 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35404443" @default.
• W4223493340 hasPublicationYear "2022" @default.
• W4223493340 type Work @default.
• W4223493340 citedByCount "5" @default.
• W4223493340 countsByYear W42234933402022 @default.
• W4223493340 countsByYear W42234933402023 @default.
• W4223493340 crossrefType "journal-article" @default.
• W4223493340 hasAuthorship W4223493340A5010791019 @default.
• W4223493340 hasAuthorship W4223493340A5010891460 @default.
• W4223493340 hasAuthorship W4223493340A5015612720 @default.
• W4223493340 hasAuthorship W4223493340A5017177249 @default.
• W4223493340 hasAuthorship W4223493340A5027431274 @default.
• W4223493340 hasAuthorship W4223493340A5031777632 @default.
• W4223493340 hasAuthorship W4223493340A5034105859 @default.
• W4223493340 hasAuthorship W4223493340A5036818390 @default.
• W4223493340 hasAuthorship W4223493340A5038129366 @default.
• W4223493340 hasAuthorship W4223493340A5053052330 @default.
• W4223493340 hasAuthorship W4223493340A5053255415 @default.
• W4223493340 hasAuthorship W4223493340A5056837393 @default.
• W4223493340 hasAuthorship W4223493340A5066122910 @default.
• W4223493340 hasAuthorship W4223493340A5066290988 @default.
• W4223493340 hasAuthorship W4223493340A5079004439 @default.
• W4223493340 hasAuthorship W4223493340A5080482957 @default.
• W4223493340 hasAuthorship W4223493340A5085405152 @default.
• W4223493340 hasAuthorship W4223493340A5087336206 @default.
• W4223493340 hasAuthorship W4223493340A5087782965 @default.
• W4223493340 hasAuthorship W4223493340A5088995687 @default.
• W4223493340 hasBestOaLocation W42234933401 @default.
• W4223493340 hasConcept C126322002 @default.
• W4223493340 hasConcept C159110408 @default.
• W4223493340 hasConcept C204243189 @default.
• W4223493340 hasConcept C2778227246 @default.
• W4223493340 hasConcept C2779951463 @default.
• W4223493340 hasConcept C2780739268 @default.
• W4223493340 hasConcept C3019894029 @default.
• W4223493340 hasConcept C502942594 @default.
• W4223493340 hasConcept C535046627 @default.
• W4223493340 hasConcept C71924100 @default.

• next